CAMP4 Therapeutics Corporation (CAMP) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CAMP Revenue Growth
Revenue Breakdown (FY 2022)
CAMP's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
By Geography
CAMP Revenue Analysis (2013–2024)
As of May 8, 2026, CAMP4 Therapeutics Corporation (CAMP) generated trailing twelve-month (TTM) revenue of $3.8 million. The most recent quarter (Q3 2025) recorded $795,000 in revenue, down 46.9% sequentially.
Looking at the longer-term picture, CAMP's 5-year compound annual growth rate (CAGR) stands at -71.8%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $366.1 million in 2019.
Revenue diversification analysis shows CAMP's business is primarily driven by Product (64%), and Application Subscriptions And Other Services (36%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RARE (+13.3% YoY), FOLD (+20.0% YoY), and ACAD (+9.9% YoY). Compare CAMP vs RARE →
CAMP Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CAMPCurrent | $4M | - | -71.8% | -8142.3% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 KRYS | $389M | +25.1% | - | 41.5% |
CAMP Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $652K | +86.3% | $652K | 100.0% | $-53,088,000 | -8142.3% |
| 2023 | $350K | - | $350K | 100.0% | $-51,879,000 | -14822.6% |
| 2022 | $0 | -100.0% | $0 | - | $-45,001,000 | - |
| 2021 | $295.8M | -4.1% | $121.9M | 41.2% | $-15,313,000 | -5.2% |
| 2020 | $308.6M | -15.7% | $122.4M | 39.7% | $-3,869,000 | -1.3% |
| 2019 | $366.1M | +0.6% | $143.3M | 39.1% | $-16,770,000 | -4.6% |
| 2018 | $363.8M | -0.6% | $147.8M | 40.6% | $19.7M | 5.4% |
| 2017 | $365.9M | +4.2% | $150.9M | 41.2% | $8.0M | 2.2% |
| 2016 | $351.1M | +25.1% | $143.4M | 40.8% | $1.3M | 0.4% |
| 2015 | $280.7M | +12.0% | $103.0M | 36.7% | $28.1M | 10.0% |
See CAMP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAMP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CAMP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCAMP — Frequently Asked Questions
Quick answers to the most common questions about buying CAMP stock.
Is CAMP's revenue growth accelerating or slowing?
CAMP TTM revenue: $4M. YoY growth: N/A. 5-year CAGR: -71.8%.
What is CAMP's long-term revenue growth rate?
CAMP4 Therapeutics Corporation's 5-year revenue CAGR of -71.8% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CAMP's revenue distributed by segment?
CAMP reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.